Akari Therapeutics PLC

AKTX06 Dec 2024
Healthcare
$1.31
-0.02 (-2.31%)
Lowest Today
$1.22
Highest Today
$1.4
Today’s Open
$1.31
Prev. Close
$1.3
52 Week High
$4.4
52 Week Low
$0.9
To Invest in Akari Therapeutics PLC

Akari Therapeutics PLC

Healthcare
AKTX06 Dec 2024
-0.02 (-2.31%)
1M
3M
6M
1Y
5Y
Low
$1.22
Day’s Range
High
$1.4
1.22
52 Week Low
$0.9
52-Week Range
52 Week High
$4.4
0.9
1 Day
-
1 Week
+7.31%
1 month return
-46.34%
3 month return
-60.12%
6 month return
-41.97%
1 Year return
-56.86%
3 Years return
-95.6%
5 Years return
-96.64%
10 Years return
-
Institutional Holdings
Omnia Family Wealth, LLC
0.35
Citadel Advisors Llc
0.13
HPM Partners LLC
0.1
Cresset Asset Management, LLC
0.07
Renaissance Technologies Corp
0.07
LUX IM Global Medtech HX
0.05
Fidelity Nasdaq Composite Index
0.01

Market Status

Fundamentals
Market Cap
30.35 mln
PB Ratio
3.07
PE Ratio
0
Enterprise Value
30.94 mln
Total Assets
4.36 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Organisation
Akari Therapeutics PLC
Employees
6
Industry
Biotechnology
CEO
Dr. Samir Rashmikant Patel M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step